Merck Exec Adam Schechter to Step Down, C-Suite Adds Two

Xconomy New York — 

Adam Schechter, president of global human health at Merck (NYSE: MRK), is stepping down from the position at the end of this year and shifting to an advisory role to the CEO, the company announced Monday. Schechter, who joined the Kenilworth, NJ, pharmaceutical giant in 1988, has been in his current post since 2010.

Merck also announced that it is creating two new executive positions overseeing its commercial organization. Frank Clyburn, who is currently president of Merck’s global oncology business, will become chief commercial officer. Michael Nally, who most recently led the company’s vaccines business, will become chief marketing officer. Both Clyburn and Nally will start their new roles on Jan. 1.